Explore the evolving role of Trop-2 in non-small cell lung cancer, including measurement techniques and emerging therapeutic insights.
Back
Understanding the Role of TROP2 in NSCLC
Experts examine the evolving role of TROP2 in non–small cell lung cancer, highlighting the limitations of conventional IHC and the potential of quantitative continuous scoring (QCS) and normalized membrane ratio (NMR) as more reliable, predictive biomarkers for TROP2-directed antibody–drug conjugates.
Understanding the Role of TROP2 in NSCLC
Episodes
All
All
Exploring the complexities of Trop-2 expression in cancer, this discussion highlights challenges in measurement and its implications for treatment efficacy.
Discover the groundbreaking QCS method for measuring Trop-2 in lung cancer, enhancing accuracy and objectivity in biomarker assessment.
Recent studies on Trop2-ADC reveal promising predictive biomarkers for lung cancer treatment, sparking excitement while urging caution for further research.
Explore the evolving role of Trop-2 in non-small cell lung cancer and the importance of larger studies and biomarkers for future treatments.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5